Metabolic Diseases

Since the first decade of the new millennium, the focus of drug and device development in the metabolic disease space has undergone a significant transition. Emerging opportunities in conditions like diabetes, fatty liver disease, and obesity have begun to displace earlier priorities. Recognizing the critical role metabolic disorders play in CNS health, we identified a growing need to support clients with their MASH study requirements. In response, we have carefully assembled a world-class team to expertly manage these trials. With membership in the FNIH Biomarkers Consortium and representation on the Metabolic Diseases Steering Committee, our subject matter experts are at the forefront of supporting these crucial development programs, driving innovation and advancing healthcare solutions. Our capabilities in this space include, but are not limited to:

  • Glucose Clamps
  • Oral Glucose and Mixed Meal Tolerance Testing
  • Intravenous Glucose Tolerance Testing
  • Insulin Tolerance Testing
  • Maximum Pancreatic Stimulation Tests
  • Graded Glucose Infusions
  • Stable Isotope Dilution Methods
  • De Novo Lipogenesis Testing
  • Gastric Emptying by Scintigraphy or Spirulina Breath Testing
  • Universal Eating Monitor (UEM)
  • Flow Mediated Dilation (FMD)
  • Indirect Calorimetry
  • DEXA
  • MRI
  • Ultrasonography
  • FibroScan®
  • Biopsy (Liver, Adipose, Muscle, etc)